Toll Free: 1-888-928-9744

Arrhythmias - Pipeline Review, H2 2017

Published: Aug 8, 2017 | Pages: 46 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Arrhythmias - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Arrhythmias - Pipeline Review, H2 2017, provides an overview of the Arrhythmias (Cardiovascular) pipeline landscape.

An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. Signs and symptoms include anxiety, weakness, dizziness, and light-headedness, fainting or nearly fainting, sweating, shortness of breath and chest pain. Treatment includes anti-arrhythmics and anticoagulants. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Arrhythmias - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Arrhythmias (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Arrhythmias (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Arrhythmias (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Arrhythmias (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Arrhythmias (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Arrhythmias (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Arrhythmias (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Arrhythmias (Cardiovascular)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Arrhythmias (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Arrhythmias (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Arrhythmias - Overview Arrhythmias - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Arrhythmias - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Arrhythmias - Companies Involved in Therapeutics Development Cynata Therapeutics Ltd Gilead Sciences Inc LATITUDE Pharmaceuticals Inc Ono Pharmaceutical Co Ltd Orion Oyj SignPath Pharma Inc Arrhythmias - Drug Profiles amiodarone - Drug Profile Product Description Mechanism Of Action R&D Progress Antisense Oligonucleotides to Activate hERG1 for Long-QT Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress efsevin - Drug Profile Product Description Mechanism Of Action R&D Progress EU-8120 - Drug Profile Product Description Mechanism Of Action R&D Progress GS-967 - Drug Profile Product Description Mechanism Of Action R&D Progress KN-93 - Drug Profile Product Description Mechanism Of Action R&D Progress landiolol - Drug Profile Product Description Mechanism Of Action R&D Progress M-201A - Drug Profile Product Description Mechanism Of Action R&D Progress ORM-10103 - Drug Profile Product Description Mechanism Of Action R&D Progress PAM-4 - Drug Profile Product Description Mechanism Of Action R&D Progress PP-1 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Target FKBP1A for Cardiovascular Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress SPP-4040 - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Cardiovacular Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress VKII-86 - Drug Profile Product Description Mechanism Of Action R&D Progress Arrhythmias - Dormant Projects Arrhythmias - Discontinued Products Arrhythmias - Product Development Milestones Featured News & Press Releases Apr 19, 2017: Cynata Advances to Pre-IND Meeting with US FDA Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Arrhythmias, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Arrhythmias - Pipeline by Cynata Therapeutics Ltd, H2 2017 Arrhythmias - Pipeline by Gilead Sciences Inc, H2 2017 Arrhythmias - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2017 Arrhythmias - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 Arrhythmias - Pipeline by Orion Oyj, H2 2017 Arrhythmias - Pipeline by SignPath Pharma Inc, H2 2017 Arrhythmias - Dormant Projects, H2 2017 Arrhythmias - Discontinued Products, H2 2017


List of Figures
Number of Products under Development for Arrhythmias, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Number of Products by Top 10 Targets, H2 2017 Number of Products by Stage and Top 10 Targets, H2 2017 Number of Products by Top 10 Mechanism of Actions, H2 2017 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...

Global heat transfer fluids market size is likely to be valued at USD 3.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing demand for for heat recovery management in industries such as metal processing, pharmaceutica

Read More...

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify